• This record comes from PubMed

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor

. 2020 Nov ; 9 (21) : 8258-8265. [epub] 20200922

Language English Country United States Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid32960498

BACKGROUND: Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. METHODS: We used the Swedish Cancer Registry (1990-2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC-SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. RESULTS: Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non-Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. CONCLUSIONS: Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.

See more in PubMed

Owen LJ. Multiple malignant neoplasms. JAMA. 1921;76:1329‐1333.

Chattopadhyay S, Zheng G, Hemminki O, Forsti A, Sundquist K, Hemminki K. Prostate cancer survivors: risk and mortality in second primary cancers. Cancer Med. 2018;7(11):5752‐5759. PubMed PMC

Chattopadhyay S, Hemminki A, Försti A, Sundquist K, Sundquist J, Hemmiinki K. Familial risks and mortality in second primary cancers in melanoma. JNCI Cancer Spectrum. 2019;2(4):pky068. PubMed PMC

Eichenauer DA, Boll B, Diehl V. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opin Pharmacother. 2014;15(8):1139‐1151. PubMed

Honecker F, Aparicio J, Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow‐up. Annals Oncol. 2018;29(8):1658‐1686. PubMed

Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950–1997. Radiation Res. 2003;160(4):381‐407. PubMed

Hemminki K, Lenner P, Sundquist J, Bermejo JL. Risk of subsequent solid tumors after non‐Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis. J Clin Oncol. 2008;26:1850‐1857. PubMed

Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nature Rev Clin Oncol. 2013;10(5):289‐301. PubMed

Galdiero MR, Marone G, Mantovani A. Cancer inflammation and cytokines. Cold Spring Harbor Perspectives Biol. 2018;10(8):a028662. PubMed PMC

Shalapour S, Karin M. Pas de Deux: control of anti‐tumor immunity by cancer‐associated inflammation. Immunity. 2019;51(1):15‐26. PubMed PMC

Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511‐519. PubMed

Harms PW, Harms KL, Moore PS, et al. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nature Rev Clin Oncol. 2018;15(12):763‐776. PubMed PMC

Rangwala S, Tsai KY. Roles of the immune system in skin cancer. Br J Dermatol. 2011;165(5):953‐965. PubMed PMC

Hortlund M, Arroyo Muhr LS, Storm H, Engholm G, Dillner J, Bzhalava D. Cancer risks after solid organ transplantation and after long‐term dialysis. Int J Cancer. 2017;140(5):1091‐1101. PubMed

Harwood CA, Toland AE, Proby CM, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017;177(5):1217‐1224. PubMed

Friman V, Winqvist O, Blimark C, Langerbeins P, Chapel H, Dhalla F. Secondary immunodeficiency in lymphoproliferative malignancies. Hematol Oncol. 2016;34(3):121‐132. PubMed

Taniguchi K, Karin M. NF‐kappaB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol. 2018;18:309‐324. PubMed

Blomberg OS, Spagnuolo L, de Visser KE. Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. Dis Models Mechanisms. 2018;11(10):dmm036236. PubMed PMC

Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(8):2009. PubMed PMC

Chattopadhyay S, Hemminki A, Forsti A, Sundquist K, Sundquist J, Hemminki K. Second primary cancers in patients with invasive and in situ squamous cell skin carcinoma, Kaposi sarcoma and Merkel cell carcinoma: role for immune mechanisms? J Invest Dermatol. 2020;140(1):48‐55.e1. PubMed

Chattopadhyay S, Sud A, Zheng G, et al. Second primary cancers in non‐Hodgkin lymphoma: bidirectional analyses suggesting role for immune dysfunction. Int J Cancer. 2018;143:2449‐2457. PubMed

Chattopadhyay S, Zheng G, Sud A, et al. Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden. Lancet Haematol. 2018;5(8):e368‐e377. PubMed

Pukkala E, Engholm G, Højsgaard Schmidt LK, et al. Nordic cancer registries ‐ an overview of their procedures and data comparability. Acta Oncol. 2018;57:440‐455. PubMed

Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nature Rev Dis Primers. 2017;3:16096. PubMed PMC

Fridman WH, Zitvogel L, Sautes‐Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nature Rev Clin Oncol. 2017;14(12):717‐734. PubMed

Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125(9):3347‐3355. PubMed PMC

Taube JM, Galon J, Sholl LM, et al. Implications of the tumor immune microenvironment for staging and therapeutics. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc. 2018;31(2):214‐234. PubMed PMC

Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995;60:183‐189. PubMed

Galluzzi L, Chan TA, Kroemer G, Wolchok JD, Lopez‐Soto A. The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459):eaat7807. PubMed

Bedognetti D, Ceccarelli M, Galluzzi L, et al. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019;7(1):131. PubMed PMC

Giraldo NA, Sanchez‐Salas R, Peske JD, et al. The clinical role of the TME in solid cancer. Br J Cancer. 2019;120(1):45‐53. PubMed PMC

Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48(4):812‐30.e14. PubMed PMC

Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128‐2139. PubMed

Liu H, Hemminki K, Sundquist J. Renal cell carcinoma as first and second primary cancer: etiological clues from the Swedish Family‐Cancer Database. J Urol. 2011;185(6):2045‐2049. PubMed

Zur HH. The search for infectious causes of human cancers: where and why. Virology. 2009;392:1‐10. PubMed

Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4(9):e609‐e616. PubMed

Back

Find record

Citation metrics

Archiving options